ECSP18030976A - Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento - Google Patents
Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamientoInfo
- Publication number
- ECSP18030976A ECSP18030976A ECIEPI201830976A ECPI201830976A ECSP18030976A EC SP18030976 A ECSP18030976 A EC SP18030976A EC IEPI201830976 A ECIEPI201830976 A EC IEPI201830976A EC PI201830976 A ECPI201830976 A EC PI201830976A EC SP18030976 A ECSP18030976 A EC SP18030976A
- Authority
- EC
- Ecuador
- Prior art keywords
- dihydroisoquinolin
- ethanone
- dichlorophenyl
- hydroxy
- methyl
- Prior art date
Links
- -1 2,6-DICHLOROPHENYL Chemical class 0.000 title 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 title 1
- XHCSBQBBGNQINS-DOTOQJQBSA-N 2-(2,6-dichlorophenyl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(3-hydroxy-3-methylbutyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone Chemical compound N1([C@H](C2=CC=CC(CCC(C)(C)O)=C2C[C@@H]1CO)C)C(=O)CC1=C(Cl)C=CC=C1Cl XHCSBQBBGNQINS-DOTOQJQBSA-N 0.000 abstract 2
- 208000028698 Cognitive impairment Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a una forma cristalina de 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona, y composiciones farmacéuticas de la misma. La invención además proporciona métodos para usar una forma cristalina de 2-(2,6-diclorofenil)-1-[(1S,3R)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1H)-il]etanona para tratar deterioro cognitivo asociado con la enfermedad de Parkinson o esquizofrenia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562245391P | 2015-10-23 | 2015-10-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18030976A true ECSP18030976A (es) | 2018-05-31 |
Family
ID=57233858
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI201830976A ECSP18030976A (es) | 2015-10-23 | 2018-04-20 | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento |
Country Status (13)
| Country | Link |
|---|---|
| CN (1) | CN108137506A (es) |
| AR (1) | AR106332A1 (es) |
| AU (1) | AU2016341115A1 (es) |
| CA (1) | CA2999332A1 (es) |
| DO (1) | DOP2018000103A (es) |
| EA (1) | EA201890525A1 (es) |
| EC (1) | ECSP18030976A (es) |
| IL (1) | IL257872A (es) |
| MX (1) | MX2018004794A (es) |
| PE (1) | PE20181296A1 (es) |
| PH (1) | PH12018500859A1 (es) |
| TW (1) | TW201725199A (es) |
| WO (1) | WO2017070068A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI725408B (zh) * | 2018-04-20 | 2021-04-21 | 美商美國禮來大藥廠 | 多巴胺d1受體正向異位調節劑 |
| MD3897578T2 (ro) | 2018-12-18 | 2025-04-30 | Lilly Co Eli | Regimuri de dozare pentru utilizarea LY3154207 în tratamentul tulburărilor dopaminergice ale SNC |
| TWI825323B (zh) * | 2019-06-18 | 2023-12-11 | 美商美國禮來大藥廠 | 用於製備2-(2,6-二氯苯基)-1-[(1s,3r)-3-(羥甲基)-5-(3-羥基-3-甲基丁基)-1-甲基-3,4-二氫異喹啉-2(1h)-基]乙烯酮之方法及中間物 |
| AU2022234744B2 (en) * | 2021-03-08 | 2025-06-26 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis |
| AU2022234226B2 (en) * | 2021-03-09 | 2025-08-14 | Eli Lilly And Company | Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression |
| CN113264926A (zh) * | 2021-05-31 | 2021-08-17 | 东北林业大学 | 一种牡荆素与利血平的共晶及其制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236934A (en) * | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| EP2125741A1 (en) * | 2007-03-01 | 2009-12-02 | Janssen Pharmaceutica, N.V. | Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor |
| US20120252853A1 (en) * | 2011-04-01 | 2012-10-04 | H. Lundbeck A/S | Positive allosteric modulators of nicotinic acetylcholine receptor |
| JO3316B1 (ar) * | 2013-05-30 | 2019-03-13 | Lilly Co Eli | مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل |
-
2016
- 2016-10-13 AR ARP160103122A patent/AR106332A1/es unknown
- 2016-10-14 TW TW105133203A patent/TW201725199A/zh unknown
- 2016-10-18 EA EA201890525A patent/EA201890525A1/ru unknown
- 2016-10-18 MX MX2018004794A patent/MX2018004794A/es unknown
- 2016-10-18 PE PE2018000570A patent/PE20181296A1/es not_active Application Discontinuation
- 2016-10-18 CN CN201680061907.6A patent/CN108137506A/zh active Pending
- 2016-10-18 AU AU2016341115A patent/AU2016341115A1/en not_active Abandoned
- 2016-10-18 WO PCT/US2016/057447 patent/WO2017070068A1/en not_active Ceased
- 2016-10-18 CA CA2999332A patent/CA2999332A1/en not_active Abandoned
-
2018
- 2018-03-05 IL IL257872A patent/IL257872A/en unknown
- 2018-04-20 EC ECIEPI201830976A patent/ECSP18030976A/es unknown
- 2018-04-20 PH PH12018500859A patent/PH12018500859A1/en unknown
- 2018-04-20 DO DO2018000103A patent/DOP2018000103A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20181296A1 (es) | 2018-08-07 |
| CA2999332A1 (en) | 2017-04-27 |
| AU2016341115A1 (en) | 2018-04-12 |
| CN108137506A (zh) | 2018-06-08 |
| DOP2018000103A (es) | 2018-10-31 |
| MX2018004794A (es) | 2018-06-19 |
| AR106332A1 (es) | 2018-01-03 |
| TW201725199A (zh) | 2017-07-16 |
| PH12018500859A1 (en) | 2018-10-29 |
| EA201890525A1 (ru) | 2018-09-28 |
| WO2017070068A1 (en) | 2017-04-27 |
| IL257872A (en) | 2018-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18030976A (es) | Forma cristalina de 2-(2,6-diclorofenil)-1-[(1s,3r)-3-(hidroximetil)-5-(3-hidroxi-3-metilbutil)-1-metil-3,4-dihidroisoquinolin-2(1h)-il]etanona para el tratamiento | |
| PE20152032A1 (es) | Compuestos de 3,4-dihidroisoquinolin-2(1h)-il | |
| PT3399962T (pt) | Composição oftálmica para o tratamento da doença do olho seco | |
| EA201691997A1 (ru) | Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы | |
| HUE059387T2 (hu) | Parkinson-kór kezelése | |
| MX381224B (es) | Potentes moduladores de gamma-secretasa. | |
| EA201691831A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| NZ746468A (en) | Methods of treating ocular conditions | |
| MX2018001592A (es) | Composiciones y metodos para el tratamiento y la prevencion de trastornos neurodegenerativos. | |
| EA201692111A1 (ru) | Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний | |
| EA201691788A1 (ru) | Гетероароматические соединения и их применение в качестве допаминовых d1 лигандов | |
| MX2016008968A (es) | Compuestos organicos. | |
| LT3413870T (lt) | Igmesinas, skirtas panaudoti alzheimerio ligos gydymui | |
| MA39450A1 (fr) | Sels pharmaceutiquement acceptables d'énantiomères de pirlindole s'utilisant en médecine | |
| EA201792558A1 (ru) | Противогрибковый 4-(4-(4-(((3r,5r)-5-((1h-1,2,4-триазол-1-ил)метил)-5-(2,4-дифторфенил)тетрагидрофуран-3-ил)метокси)-3-метилфенил)пиперазин-1-ил)-n-(2-гидроксициклогексил)бензамид или его фармацевтически приемлемая соль | |
| CR20170426A (es) | Inhibidores de bace 1 | |
| ZA201902715B (en) | Enzyme composition for therapeutic management of muscle soreness | |
| IL260009B (en) | Novel bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease | |
| CO2017000019A2 (es) | Forma polimórfica novedosa del clorhidrato de n-[2-(6-fluoro-1h-indol-3-il)etil]-3-(2,2,3,3-tetrafluoropropoxi)bencilamina para el tratamiento del alzhéimer | |
| MA40065A (fr) | N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson | |
| EA201790231A1 (ru) | Профилактическое или терапевтическое средство для лечения болезней заднего сегмента глаза |